Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia

Steven M. Trifilio; Alfred W. Rademaker; Diane Newman; Katherine Coyle; Katrin Carlson-Leuer; Jayesh Mehta; Jessica Altman; Olga Frankfurt; Martin S. Tallman

doi:10.1016/j.leukres.2011.10.027

Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia

Steven M. Trifilio^*, Alfred W. Rademaker, Diane Newman, Katherine Coyle, Katrin Carlson-Leuer, Jayesh Mehta, Jessica Altman, Olga Frankfurt, Martin S. Tallman

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

Mitoxantrone and etoposide (ME) salvage regimens have been successfully used for the treatment of primary induction failure or relapsed acute myeloid leukemia (AML). Whether the addition of intermediate dose cytarabine to ME increases complete remissions is unknown. To date, these regimens have not been directly compared. Herein, we report the response to treatment with a fixed dosing schedule of ME or MEC in 65 patients treated for primary refractory or relapsed AML with intermediate or unfavorable risk cytogenetics. Differences in CR between ME and MEC subsets were analyzed to determine the effect of cytarabine to ME.

Original language	English (US)
Pages (from-to)	394-396
Number of pages	3
Journal	Leukemia Research
Volume	36
Issue number	4
DOIs	https://doi.org/10.1016/j.leukres.2011.10.027
State	Published - Apr 2012

Keywords

Acute myeloid leukemia
Cytarabine
Etoposide
Mitoxantrone

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.leukres.2011.10.027

Cite this

Trifilio, S. M., Rademaker, A. W., Newman, D., Coyle, K., Carlson-Leuer, K., Mehta, J., Altman, J., Frankfurt, O., & Tallman, M. S. (2012). Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia. Leukemia Research, 36(4), 394-396. https://doi.org/10.1016/j.leukres.2011.10.027

@article{c881d269155f4e8aaf5d1611c537bd99,

title = "Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia",

abstract = "Mitoxantrone and etoposide (ME) salvage regimens have been successfully used for the treatment of primary induction failure or relapsed acute myeloid leukemia (AML). Whether the addition of intermediate dose cytarabine to ME increases complete remissions is unknown. To date, these regimens have not been directly compared. Herein, we report the response to treatment with a fixed dosing schedule of ME or MEC in 65 patients treated for primary refractory or relapsed AML with intermediate or unfavorable risk cytogenetics. Differences in CR between ME and MEC subsets were analyzed to determine the effect of cytarabine to ME.",

keywords = "Acute myeloid leukemia, Cytarabine, Etoposide, Mitoxantrone",

author = "Trifilio, {Steven M.} and Rademaker, {Alfred W.} and Diane Newman and Katherine Coyle and Katrin Carlson-Leuer and Jayesh Mehta and Jessica Altman and Olga Frankfurt and Tallman, {Martin S.}",

year = "2012",

month = apr,

doi = "10.1016/j.leukres.2011.10.027",

language = "English (US)",

volume = "36",

pages = "394--396",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Ltd",

number = "4",

}

Trifilio, SM, Rademaker, AW, Newman, D, Coyle, K, Carlson-Leuer, K , Mehta, J , Altman, J, Frankfurt, O & Tallman, MS 2012, 'Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia', Leukemia Research, vol. 36, no. 4, pp. 394-396. https://doi.org/10.1016/j.leukres.2011.10.027

TY - JOUR

T1 - Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia

AU - Trifilio, Steven M.

AU - Rademaker, Alfred W.

AU - Newman, Diane

AU - Coyle, Katherine

AU - Carlson-Leuer, Katrin

AU - Mehta, Jayesh

AU - Altman, Jessica

AU - Frankfurt, Olga

AU - Tallman, Martin S.

PY - 2012/4

Y1 - 2012/4

N2 - Mitoxantrone and etoposide (ME) salvage regimens have been successfully used for the treatment of primary induction failure or relapsed acute myeloid leukemia (AML). Whether the addition of intermediate dose cytarabine to ME increases complete remissions is unknown. To date, these regimens have not been directly compared. Herein, we report the response to treatment with a fixed dosing schedule of ME or MEC in 65 patients treated for primary refractory or relapsed AML with intermediate or unfavorable risk cytogenetics. Differences in CR between ME and MEC subsets were analyzed to determine the effect of cytarabine to ME.

AB - Mitoxantrone and etoposide (ME) salvage regimens have been successfully used for the treatment of primary induction failure or relapsed acute myeloid leukemia (AML). Whether the addition of intermediate dose cytarabine to ME increases complete remissions is unknown. To date, these regimens have not been directly compared. Herein, we report the response to treatment with a fixed dosing schedule of ME or MEC in 65 patients treated for primary refractory or relapsed AML with intermediate or unfavorable risk cytogenetics. Differences in CR between ME and MEC subsets were analyzed to determine the effect of cytarabine to ME.

KW - Acute myeloid leukemia

KW - Cytarabine

KW - Etoposide

KW - Mitoxantrone

UR - http://www.scopus.com/inward/record.url?scp=84857235820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857235820&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2011.10.027

DO - 10.1016/j.leukres.2011.10.027

M3 - Article

C2 - 22172465

AN - SCOPUS:84857235820

SN - 0145-2126

VL - 36

SP - 394

EP - 396

JO - Leukemia Research

JF - Leukemia Research

IS - 4

ER -

Mitoxantrone and etoposide with or without intermediate dose cytarabine for the treatment of primary induction failure or relapsed acute myeloid leukemia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this